These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22378156)

  • 21. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
    Tabrizi AR; Zehnbauer BA; Borecki IB; McGrath SD; Buchman TG; Freeman BD
    J Am Coll Surg; 2002 Mar; 194(3):267-73. PubMed ID: 11893129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.
    Adcock DM; Koftan C; Crisan D; Kiechle FL
    Arch Pathol Lab Med; 2004 Dec; 128(12):1360-3. PubMed ID: 15578879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.
    Lane S; Al-Zubiedi S; Hatch E; Matthews I; Jorgensen AL; Deloukas P; Daly AK; Park BK; Aarons L; Ogungbenro K; Kamali F; Hughes D; Pirmohamed M
    Br J Clin Pharmacol; 2012 Jan; 73(1):66-76. PubMed ID: 21692828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.
    Nagai R; Ohara M; Cavallari LH; Drozda K; Patel SR; Nutescu EA; Perera MA; Hernandez W; Kaneko N; Hibiya M; Takahashi H
    Pharmacogenomics; 2015; 16(3):217-25. PubMed ID: 25712185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
    Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
    Perera MA; Cavallari LH; Limdi NA; Gamazon ER; Konkashbaev A; Daneshjou R; Pluzhnikov A; Crawford DC; Wang J; Liu N; Tatonetti N; Bourgeois S; Takahashi H; Bradford Y; Burkley BM; Desnick RJ; Halperin JL; Khalifa SI; Langaee TY; Lubitz SA; Nutescu EA; Oetjens M; Shahin MH; Patel SR; Sagreiya H; Tector M; Weck KE; Rieder MJ; Scott SA; Wu AH; Burmester JK; Wadelius M; Deloukas P; Wagner MJ; Mushiroda T; Kubo M; Roden DM; Cox NJ; Altman RB; Klein TE; Nakamura Y; Johnson JA
    Lancet; 2013 Aug; 382(9894):790-6. PubMed ID: 23755828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
    Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
    J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
    Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
    Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Any effect of CYP2C9 variants on warfarin clearance in Chinese patients?
    You JH; Zuo Z; Lo CM; Zhou L; Yiu HH; Chau CT; Choi KC; Choi DK; Wong RS; Cheng G
    Thromb Haemost; 2007 May; 97(5):866-8. PubMed ID: 17479200
    [No Abstract]   [Full Text] [Related]  

  • 31. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.
    Flora DR; Rettie AE; Brundage RC; Tracy TS
    J Clin Pharmacol; 2017 Mar; 57(3):382-393. PubMed ID: 27539372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
    Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
    Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
    Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
    Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.
    Moyer TP; O'Kane DJ; Baudhuin LM; Wiley CL; Fortini A; Fisher PK; Dupras DM; Chaudhry R; Thapa P; Zinsmeister AR; Heit JA
    Mayo Clin Proc; 2009 Dec; 84(12):1079-94. PubMed ID: 19955245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
    Perera MA; Gamazon E; Cavallari LH; Patel SR; Poindexter S; Kittles RA; Nicolae D; Cox NJ
    Clin Pharmacol Ther; 2011 Mar; 89(3):408-15. PubMed ID: 21270790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients].
    Siguret V; Gouin I; Golmard JL; Geoffroy S; Andreux JP; Pautas E
    Rev Med Interne; 2004 Apr; 25(4):271-4. PubMed ID: 15050794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.
    Lindh JD; Holm L; Andersson ML; Rane A
    Eur J Clin Pharmacol; 2009 Apr; 65(4):365-75. PubMed ID: 19031075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.